Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors

Albers, Peter; Bender, Hans; Yılmaz, Hasan; Schoeneich, G.; Biersack, H. J.; Mueller, Stefan C.

doi:10.1016/s0090-4295(98)00576-7

Cited by 150 publications

(50 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most patients with NSGCT mature teratoma was found in the residual mass (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). In five of them (16)(17)(18)(19)(20) FDG uptake was found (SUV 1.7-3.7).…”

Section: Resultsmentioning

confidence: 99%

“…In five of them (16)(17)(18)(19)(20) FDG uptake was found (SUV 1.7-3.7). On visual analysis, only patients 16 and 17 had a suspect lesion at PET.…”

Section: Resultsmentioning

confidence: 99%

“…Albers et al [20] assessed 24 patients with NSGCT stage I to IIB who underwent FDG-PET for clinical staging. The FDG-PET scan detected six of the nine metastatic lesions.…”

Section: -Fdg Pet For Staging Germ Cell Tumours After Chemotherapy 553mentioning

confidence: 99%

“…In contrast, CT was false-positive in four of nine patients with lymph nodes of >1.0 cm, whereas FDG-PET was completely conclusive. These authors stated that FDG-PET may not be helpful in primary staging of CS I NSGCT, but it might have additional value in CS IIA patients, by omitting false-positive findings on CT. A limitation of FDG-PET and CT in initial staging of low-stage NSGCT is its inability to detect very small lesions [20]. Perhaps malignant cells are already present in the lymph node before nodal enlargement.…”

Section: -Fdg Pet For Staging Germ Cell Tumours After Chemotherapy 553mentioning

confidence: 99%

See 3 more Smart Citations

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Spermon¹,

et al. 2002

View full text Add to dashboard Cite

Objective To investigate the role of 18 fluoro-2-deoxyglucose positron emission tomography (FDG-PET) tumorous residual mass the FDG-PET scan was clearly positive; in four of 12 with mature teratoma and inflammation components retroperitoneally, the FDG-PET was also positive. In contrast, eight patients with solitary mature teratoma had a negative PET result. In four of five patients with necrosis after chemotherapy the PET result was correctly negative. All eight patients on surveillance had a negative PET scan and were free of disease at median (range) of 14 (8-18) months. Interestingly, of the 12 patients with a correct negative PET result, 11 had no mature teratoma in their primary tumour. Nine of 10 patients with SGCT were correctly staged. Two FDG-PET studies showed increased uptake; in one, a viable seminomatous mass was found and in the other there was inflammation in the residual mass. In all other patients the FDG-PET scan correctly predicted absence of viability in the residual mass. Conclusions In primary staging, FDG-PET has no benefit over CT. In re-staging, a negative FDG-PET result predicts fibrotic residual mass in seminomatous GCT. Moreover, it could be useful to predict fibrotic residual mass in NSGCT in those patients with no teratoma component in their primary tumour.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In five of them (16)(17)(18)(19)(20) FDG uptake was found (SUV 1.7-3.7). On visual analysis, only patients 16 and 17 had a suspect lesion at PET.…”

Section: Resultsmentioning

confidence: 99%

“…Albers et al [20] assessed 24 patients with NSGCT stage I to IIB who underwent FDG-PET for clinical staging. The FDG-PET scan detected six of the nine metastatic lesions.…”

Section: -Fdg Pet For Staging Germ Cell Tumours After Chemotherapy 553mentioning

confidence: 99%

Section: -Fdg Pet For Staging Germ Cell Tumours After Chemotherapy 553mentioning

confidence: 99%

See 2 more Smart Citations

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Spermon¹,

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Ultimately, 21 studies were excluded for undesirable article types (n=21), not written in English (n=6), and insufficient data (n=4), letter (n=2), case report (n=1), and review (n=8). Thus, 16 studies were included in our final dataset for the meta-analysis (Cremerius et al, 1998;Albers et al, 1999;Cremerius et al, 1999;Hain et al, 2000;Bokemeyer et al, 2002;Spermon et al, 2002;Tsatalpas et al, 2002;Lassen et al, 2003;De Santis et al, 2004;Becherer et al, 2005;de Wit et al, 2008;Hinz et al, 2008;Oechsle et al, 2008;Akbulut et al, 2011;Bachner et al, 2012;Siekiera et al, 2012). The flowchart of study selection was shown in Figure 1.…”

Section: Study Selection and Characteristics Of Studies In Our Analysismentioning

confidence: 99%

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

Zhao

Ma²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Risk factors for relapse in stage I non-seminomatous germ-cell tumors: Preliminary results of the German multicenter trial

Albers

Siener

Hartmann³

et al. 1999

Int. J. Cancer

Self Cite

View full text Add to dashboard Cite

Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors

Cited by 150 publications

References 11 publications

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

Risk factors for relapse in stage I non-seminomatous germ-cell tumors: Preliminary results of the German multicenter trial

Contact Info

Product

Resources

About

Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors

Cited by 150 publications

References 11 publications

The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

Risk factors for relapse in stage I non-seminomatous germ-cell tumors: Preliminary results of the German multicenter trial

Contact Info

Product

Resources

About

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours